Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), Human Immunodeficiency Virus (HIV), multiple sclerosis (MS) and pain, announced that it has changed the payment terms to its Cobroxin distribution agreement with XenaCare Holdings.
“In light of XenaCare’s recently launched television advertising campaign, we have decided to continue our relationship with XenaCare to help them build the Cobroxin brand,” explained Rik J. Deitsch, chairman and CEO of Nutra Pharma Corporation. “As XenaCare’s advertising continues, we remain optimistic that Cobroxin will become better known among consumers. XenaCare’s management has already informed us of improving sales exposure due to their advertising campaign. We look forward to working closely with XenaCare as they continue their ongoing advertising support for Cobroxin,” he added.
Cobroxin is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Currently, Cobroxin is available as an oral spray for treating migraine headaches, neck aches, shoulder pain, cramps, lower back pain, and neuralgia and is also available as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.
In 2009, Nutra Pharma granted an exclusive license to XenaCare Holdings to market and distribute Cobroxin in the United States.
Nutra Pharma Corporation, a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.